CANCER BREAST COMPREHENSIVE PANEL
ER & PR receptor assays are routinely performed on Breast carcinomas to assess reponsiveness to endocrine therapy and prognosis. Her-2 expression shows responsiveness to Herceptin therapy. Addition of Ki-67 further helps as a predictive and prognostic markerThese biomarkers are used for better understanding of the kinetics and effectiveness of a drug. It detects early signals of efficacy for rapidly evaluating the impact of potential disease-modifying therapies.
Parameter(s) covered : 8
Report Frequency: Sample Tue by 9 am; Report 10 Working days
Special Instruction: Provide a copy of the Histopathology report, clinical history & indicate site of biopsy.
Price : ₹ 7600.00
Parameters
- Average Intensity of Staining
- Estrogen Receptor (ER)
- HER – 2 neu (c-erb B2)
- Internal Control
- Ki 67
- PROGESTERONE RECEPTOR (PR)
- Send Out Comment
- Vip_FishAmp